[A17-30] Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07
Last updated 17.08.2017
Project no.:
A17-30
Commission:
Commission awarded on 11.07.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adults with moderate to severe plaque psoriasis
Result of dossier assessment:
Indication of considerable added benefit now also for patients who are eligible for systemic and/or phototherapy
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-08-17 A G-BA decision was published.